Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

NVO’s arch-rival, Lilly, markets tirzepatide, a dual GIP and GLP-1 receptor agonist, as Mounjaro for T2D and Zepbound for obesity ... of cognitive problems and nicotine misuse.

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Per the partial data released from that phase 3b clinical trial, over 72 weeks of once-weekly treatment with either Zepbound or Wegovy, patients taking Zepbound lost 20.2% of their weight on ...

Nicotine is the substance in tobacco that makes smoking addictive. Limited studies suggest it could temporarily improve attention and cognitive (thinking) function. However, there is not enough ...

Zyn nicotine pouches loved by young people for their appetite-suppressing effects have officially been approved in the US. The FDA said it found the pouches were a safer alternative to cigarettes ...

The Food and Drug Administration (FDA) announced on Thursday that it authorized the marketing of Zyn nicotine pouches but will be "closely monitoring youth use." "The FDA's decision recognizes the ...

The Food and Drug Administration authorized the marketing of 20 Zyn products on Thursday, marking the first such move by the regulator for the fast-growing nicotine pouches segment. The ...

Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit cigarettes. The ...

WASHINGTON — Federal health officials on Thursday backed the public health benefits of nicotine pouches, authorizing Philip Morris International’s Zyn to help adult smokers cut back or quit ...

This growth has brought controversy. Photo illustration: Alexander Hotz U.S. health officials cleared America’s most popular nicotine pouch to stay on the market, saying Zyn’s benefit as a ...